Alzamend Neuro Adds Healthy Subjects to Ongoing Mid-Stage Alzheimer's Trial

Alzamend Neuro Adds Healthy Subjects to Ongoing Mid-Stage Alzheimer's Trial
  • Alzamend Neuro Inc ALZN has dosed its first healthy adult subject in its Phase 2A multiple ascending dose (MAD) study of AL001 in subjects with dementia related to Alzheimer's. 
  • This blinded, placebo-controlled trial (AL001-02) was initiated in May 2022 and is designed to evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions and determine the maximum tolerated dose.
  • Alzamend is also pursuing AL001 for bipolar disorder, major depressive disorder, and post-traumatic stress disorder. 
  • Related: Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study.
  • Based upon a recommendation by the FDA after its review and commentary on Alzamend's pre-investigational new drug briefing package for the development of AL001, the ongoing clinical trial in Alzheimer's patients has been expanded. 
  • Alzamend will test AL001 in four healthy adult and elderly adult cohorts of eight subjects under MAD conditions.
  • AL001 is a novel lithium-salicylate-L-proline engineered ionic cocrystal lithium delivery system. 
  • Price Action: ALZN shares are up 0.01% at $1.3801 on the last check Wednesday.

Posted In: BriefsBiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneral